Note 4 - Collaboration and License Agreement (Details Textual) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended	29 Months Ended
	Nov. 06, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Mar. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 1,491	$ 1,092
3D Medicines, Inc [Member]
Proceeds from Collaborators				$ 15,000	$ 27,000
Collaborative Agreement, Maximum Clinical Development, Regulatory and Commercial Milestone Payments	$ 207,000
Collaborative Agreement, Royalty, Period After First Commercial Sale of Product (Year)	10 years
Revenue, Remaining Performance Obligation, Amount		27,000			27,000
Contract with Customer, Liability		3,600		$ 5,000	3,600
Contract with Customer, Liability, Revenue Recognized		$ 1,500
Service Period (Year)		1 year 3 months 18 days
3D Medicines, Inc [Member] | Research and Development Services [Member]
Revenue, Remaining Performance Obligation, Amount		$ 14,500			14,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total		1,500	1,100
3D Medicines, Inc [Member] | License [Member]
Revenue, Remaining Performance Obligation, Amount		12,500			$ 12,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 0	$ 0